OBJECTIVE: Diagnosing ventilator-associated pneumonia (VAP) is difficult, and misdiagnosis can lead to unnecessary and prolonged antibiotic treatment. We sought to quantify and characterize unjustified antimicrobial use for VAP and identify risk factors for continuation of antibiotics in patients without VAP after 3 days. METHODS: Patients suspected of having VAP were identified in 6 adult intensive care units (ICUs) over 1 year. A multidisciplinary adjudication committee determined whether the ICU team's VAP diagnosis and therapy were justified, using clinical, microbiologic, and radiographic data at diagnosis and on day 3. Outcomes included the proportion of VAP events misdiagnosed as and treated for VAP on days 1 and 3 and risk factors for the continuation of antibiotics in patients without VAP after day 3. RESULTS: Two hundred thirty-one events were identified as possible VAP by the ICUs. On day 1, 135 (58.4%) of them were determined to not have VAP by the committee. Antibiotics were continued for 120 (76%) of 158 events without VAP on day 3. After adjusting for acute physiology and chronic health evaluation II score and requiring vasopressors on day 1, sputum culture collection on day 3 was significantly associated with antibiotic continuation in patients without VAP. Patients without VAP or other infection received 1,183 excess days of antibiotics during the study. CONCLUSIONS: Overdiagnosis and treatment of VAP was common in this study and led to 1,183 excess days of antibiotics in patients with no indication for antibiotics. Clinical differences between non-VAP patients who had antibiotics continued or discontinued were minimal, suggesting that clinician preferences and behaviors contribute to unnecessary prescribing.
OBJECTIVE: Diagnosing ventilator-associated pneumonia (VAP) is difficult, and misdiagnosis can lead to unnecessary and prolonged antibiotic treatment. We sought to quantify and characterize unjustified antimicrobial use for VAP and identify risk factors for continuation of antibiotics in patients without VAP after 3 days. METHODS:Patients suspected of having VAP were identified in 6 adult intensive care units (ICUs) over 1 year. A multidisciplinary adjudication committee determined whether the ICU team's VAP diagnosis and therapy were justified, using clinical, microbiologic, and radiographic data at diagnosis and on day 3. Outcomes included the proportion of VAP events misdiagnosed as and treated for VAP on days 1 and 3 and risk factors for the continuation of antibiotics in patients without VAP after day 3. RESULTS: Two hundred thirty-one events were identified as possible VAP by the ICUs. On day 1, 135 (58.4%) of them were determined to not have VAP by the committee. Antibiotics were continued for 120 (76%) of 158 events without VAP on day 3. After adjusting for acute physiology and chronic health evaluation II score and requiring vasopressors on day 1, sputum culture collection on day 3 was significantly associated with antibiotic continuation in patients without VAP. Patients without VAP or other infection received 1,183 excess days of antibiotics during the study. CONCLUSIONS: Overdiagnosis and treatment of VAP was common in this study and led to 1,183 excess days of antibiotics in patients with no indication for antibiotics. Clinical differences between non-VAP patients who had antibiotics continued or discontinued were minimal, suggesting that clinician preferences and behaviors contribute to unnecessary prescribing.
Authors: Atul A Kalanuria; Donna Fellerman; Paul Nyquist; Romergryko Geocadin; Robert G Kowalski; Veronique Nussenblatt; Matthew Rajarathinam; Wendy Ziai Journal: Neurocrit Care Date: 2015-08 Impact factor: 3.210
Authors: Blaine Kenaa; Mary Elizabeth Richert; Kimberly C Claeys; Andrea Shipper; Kaede V Sullivan; Gregory M Schrank; Lyndsay M O'Hara; Daniel J Morgan; Carl Shanholtz; Surbhi Leekha Journal: Curr Infect Dis Rep Date: 2019-11-21 Impact factor: 3.725
Authors: Ariane Lewis; Sarah Wahlster; Sarah Karinja; Barry M Czeisler; W Taylor Kimberly; Aaron S Lord Journal: Br J Neurosurg Date: 2015-09-15 Impact factor: 1.596
Authors: John C O'Horo; Rahul Kashyap; Ronaldo Sevilla Berrios; Vitaly Herasevich; Priya Sampathkumar Journal: Am J Infect Control Date: 2016-02-18 Impact factor: 2.918
Authors: Guowei Li; Deborah J Cook; Lehana Thabane; Jan O Friedrich; Tim M Crozier; John Muscedere; John Granton; Sangeeta Mehta; Steven C Reynolds; Renato D Lopes; Francois Lauzier; Andreas P Freitag; Mitchell A H Levine Journal: Respir Res Date: 2016-07-11